TrialLineage Concept
Antisense oligonucleotides
Antisense oligonucleotides (ASOs) are short, synthetic strands of modified nucleic acid designed to bind specific RNA sequences in cells. By binding their target RNA, ASOs can degrade it, block its translation, or alter its splicing — allowing precise intervention at the gene-expression level.
In plain language
How ASOs work
DNA is double-stranded. RNA is usually single-stranded. An antisense oligonucleotide is a short synthetic molecule whose sequence is complementary to a specific RNA target. When introduced into cells, it binds to its target RNA through Watson-Crick base pairing and triggers one of several effects: recruiting enzymes that degrade the RNA (RNase H–mediated cleavage), physically blocking ribosome access (steric blocking), or redirecting splicing machinery.
Chemical modifications to the sugar-phosphate backbone — including phosphorothioate linkages and 2’-O-methoxyethyl (MOE) modifications — improve stability, resistance to degradation, and cellular uptake. These modifications were developed over decades and are essential to clinical viability.
Why ASOs matter
ASOs enable a drug design logic that is fundamentally different from traditional small molecules or antibodies. Instead of targeting a protein’s shape, ASOs target the RNA sequence that encodes the protein (or regulates its expression). This means any gene with a known RNA sequence is, in principle, a potential ASO target.
Approved ASO therapies include nusinersen (Spinraza) for spinal muscular atrophy and inotersen for hereditary transthyretin amyloidosis. ION582 (obudanersen) for Angelman syndrome uses the same platform chemistry and intrathecal delivery route proven with nusinersen.
Connection to the Angelman case
ION582 is designed to target UBE3A-ATS, the antisense transcript that silences the paternal UBE3A gene in neurons. By reducing UBE3A-ATS through RNase H–mediated degradation, the goal is to allow the paternal UBE3A allele to be expressed. The entire therapeutic rationale depends on ASO technology’s ability to reach CNS neurons and selectively degrade a specific non-coding RNA.
Related concepts